Questionable recommendations for cholinesterase inhibitor use in AD

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1500, 2005-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Melaena following Use of the Cholinesterase Inhibitor Rivastigmine

By Pietro Gareri   Luca Gallelli  

Clinical Drug Investigation, Vol. 25, Iss. 3, 2005-01 ,pp. : 215-217

Adis International

Access to resources Recommend Favorite

WTP for cholinesterase inhibitors high in AD

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 440, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Leukotriene antagonist use questionable in the US

By  

Inpharma, Vol. 1, Iss. 1438, 2004-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Assessing the real worth of cholinesterase inhibitors in AD

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 449, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Influence of Cholinesterase Inhibitor on Clinical Symptoms of Schizophrenia

By  

Current Psychopharmacology, Vol. 6, Iss. 1, 2017-04 ,pp. : 27-35

Bentham Science Publishers

Access to resources Recommend Favorite